Last reviewed · How we verify
EPs® 7630
At a glance
| Generic name | EPs® 7630 |
|---|---|
| Also known as | Pelargonium root liquid extract, dried, Group 1 |
| Sponsor | Dr. Willmar Schwabe GmbH & Co. KG |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Management of Acute Bronchitis With Pelargonium Sidoides Extract (NA)
- Hand, Foot, and Mouth Disease: Could EPs®7630 be a Treatment Option (PHASE2, PHASE3)
- Safety and Intake Effect of EPs® 7630 (an Extract of the Roots of Pelargonium Sidoides) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EPs® 7630 CI brief — competitive landscape report
- EPs® 7630 updates RSS · CI watch RSS
- Dr. Willmar Schwabe GmbH & Co. KG portfolio CI